Amgen (NASDAQ:AMGN) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Amgen (NASDAQ:AMGN) from a hold rating to a buy rating in a research note released on Saturday.

A number of other research firms also recently commented on AMGN. BMO Capital Markets boosted their price target on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Argus dropped their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $370.07.

Amgen Price Performance

Amgen stock opened at $410.95 on Friday. The stock’s fifty day moving average price is $362.77 and its two-hundred day moving average price is $356.24. Amgen has a one year low of $269.77 and a one year high of $418.40. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market cap of $222.17 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 3.83 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen will post 22.78 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s payout ratio is presently 62.65%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Oxbow Advisors LLC increased its holdings in Amgen by 0.8% in the 2nd quarter. Oxbow Advisors LLC now owns 11,698 shares of the medical research company’s stock worth $4,236,000 after purchasing an additional 92 shares in the last quarter. Cypress Asset Management Inc. TX boosted its stake in shares of Amgen by 6.8% during the second quarter. Cypress Asset Management Inc. TX now owns 4,881 shares of the medical research company’s stock valued at $1,768,000 after purchasing an additional 310 shares in the last quarter. Main Street Financial Solutions LLC bought a new stake in shares of Amgen during the second quarter worth about $1,662,000. Fidelity D & D Bancorp Inc. grew its holdings in shares of Amgen by 14.8% during the second quarter. Fidelity D & D Bancorp Inc. now owns 754 shares of the medical research company’s stock worth $273,000 after purchasing an additional 97 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC increased its stake in shares of Amgen by 8.5% in the second quarter. Alpine Woods Capital Investors LLC now owns 25,029 shares of the medical research company’s stock valued at $9,064,000 after buying an additional 1,965 shares during the period. Institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.